On August 19, ZAI LAB rose 6.27% in regular trading to HK$20.46, with turnover of approximately HK$64.04 million. The rally was driven by the successful Phase 3 clinical trial results of efgartigimod, an FcRn-targeting therapy developed by partner argenx, for which ZAI LAB holds Greater China rights, coupled with a broker initiating coverage with an Overweight rating.

According to disclosures, efgartigimod is being continuously evaluated for multiple autoimmune rheumatic diseases. Clinical data demonstrated that patient improvements were evident from early in the treatment period and sustained throughout the study duration, with highly consistent treatment effects observed across both immune-mediated necrotizing myopathy and dermatomyositis subgroups. The breadth of potential indications reinforces the drug's long-term commercial value for ZAI LAB in the Greater China region.

The stock has accumulated significant momentum following its Q2 earnings release on August 6, which showed product revenue of US$105.8 million, up 11% sequentially, driven by stable Zejula performance and continued efgartigimod volume growth. Additionally, RTW Investments increased its stake by approximately 4.77 million shares at US$25.41 per share on August 12, signaling institutional confidence.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)